Literature DB >> 9191187

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma.

D R Anderson1, A Grillo-López, C Varns, K S Chambers, N Hanna.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9191187     DOI： 10.1042/bst0250705

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN： 0300-5127            Impact factor:   5.407


× No keyword cloud information.
  52 in total

Review 1.  B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.

Authors:  T Shaw; J Quan; M C Totoritis
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

2.  Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking.

Authors:  Tammy L Unruh; Haidong Li; Cathlin M Mutch; Neda Shariat; Lana Grigoriou; Ratna Sanyal; Christopher B Brown; Julie P Deans
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

Review 3.  Immunosuppressive preconditioning or induction regimens : evidence to date.

Authors:  Henkie P Tan; Marc C Smaldone; Ron Shapiro
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Induction therapy in renal transplantation : an overview of current developments.

Authors:  Gaetano Ciancio; George W Burke; Joshua Miller
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.

Authors:  Eynav Klechevsky; Michael Gallegos; Galit Denkberg; Karolina Palucka; Jacques Banchereau; Cyril Cohen; Yoram Reiter
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 6.  Ras and Rap1: A tale of two GTPases.

Authors:  Seema Shah; Ethan J Brock; Kyungmin Ji; Raymond R Mattingly
Journal:  Semin Cancer Biol       Date:  2018-04-03       Impact factor: 15.707

7.  Promising treatments of tomorrow for multiple sclerosis.

Authors:  Daniel M Harrison; Peter A Calabresi
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

8.  CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.

Authors:  Lawrence G Lum; Archana Thakur; Qin Liu; Abhinav Deol; Zaid Al-Kadhimi; Lois Ayash; Muneer H Abidi; Cassara Pray; Elyse N Tomaszewski; Patricia A Steele; Dana L Schalk; Hiroshi Yano; Alice Mitchell; Melissa Dufresne; Joseph P Uberti; Voravit Ratanatharathorn
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-22       Impact factor: 5.742

9.  Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma.

Authors:  Jing Yang; Yabing Cao; Sungyongl Hong; Haiyan Li; Jianfei Qian; Larry W Kwak; Qing Yi
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

10.  CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma.

Authors:  Yasutaka Kakinoki; Hiroya Kubota; Yasushi Yamamoto
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.